Compositions and methods for treating multiple myeloma

A compound having the structure of Formula (I):

• wherein R1-R5 are independently selected from hydrogen, —F;
• —Cl;
• —Br;
• —I;
• —OH;
• —OR*;
• —NH2;
• —NHR*;
• —N(R*)2;
• —N(R*)3+;
• —N(R*)—OH;
• —N(→*O)(R*)2;
• —O—N(R*)2;
• —N(R*)—O—R*;
• —N(R*)—N(R*)2;
• —C═N—R*;
• —N═C(R*)2;
• —C═N—N(R*)2;
• —C(═NR*)(—N(R*)2);
• —C(H)(═N—OH);
• —SH;
• —SR*;
• —CN;
• —NC;
• —C(═O)—R*;
• —CHO;
• —CO2H;
• —CO2—;
• —CO2R*;
• —C(═O)—S—R*;
• —O—(C═O)—H;
• —O—(C═O)—R*;
• —S—C(═O)—R*;
• —(C═O)—NH2;
• —C(═O)—N(R*)2;
• —C(═O)—NHNH2;
• —O—C(═O)—NHNH2;
• —C(═S)—NH2;
• —(C═S)—N(R*)2;
• —N(R*)—CHO;
• —N(R*)—C(═O)—R*;
• —C(═NR*)—O—R*;
• —O—C(═NR*)—R*;
• —SCN;
• —NCS;
• —NSO;
• —SSR*;
• —N(R*)—C(═O)—N(R*)2;
• —N(R*)—C(═S)—N(R*)2;
• —S(═O)1-2—R*;
• —O—S(═O)2—R*;
• —S(═O)2—OR*;
• —N(R*)—S(═O)2—R*;
• —S(═O)2—N(R*)2;
• —O—SO3;
• —O—S(═O)2—OR*;
• —O—S(═O)—OR*;
• —O—S(═O)—R*;
• —S(═O)—OR*;
• —S(═O)—R*;
• —NO;
• —NO2;
• —NO3;
• —O—NO;
• —O—NO2;
• —N3;
• —N2—R*;
• —N(C2H4);
• —Si(R*)3;
• —CF3;
• —O—CF3;
• —O—CH3;
• —O—(CH2)1-6CH3;
• —PR*2;
• —O—P(═O)(OR*)2;
• and —P(═O)(OR*)2;
• R* is, independently at each occurrence from hydrogen, and a C1-10 hydrocarbon;
• where at least one of R1-R5 is not hydrogen;
• or pharmaceutically acceptable salts thereof.